LL-37 vs KPV

LL-37 is the only human cathelicidin antimicrobial peptide, a 37-amino-acid fragment cleaved from the hCAP-18 precursor protein. Beyond its broad-spectrum antimicrobial activity against bacteria, fungi, and enveloped viruses, LL-37 functions as a significant immunomodulatory molecule. Preclinical studies have documented its effects on wound closure, angiogenesis, and modulation of NF-kB-mediated inflammatory cascades. KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (alpha-MSH). Its primary mechanism of interest involves direct inhibition of the NF-kB inflammatory signaling pathway, which plays a central role in intestinal and tissue inflammation. KPV retains the anti-inflammatory properties of full-length alpha-MSH without engaging melanocortin receptors, making it a focused tool for studying NF-kB-driven inflammatory processes.

LL-37

Structure 37-amino-acid cathelicidin
Primary Mechanism Membrane disruption, immune modulation
Research Focus Antimicrobial defense, wound healing
Pathway Breadth Broad (TLR, NF-kB, angiogenesis)
Antimicrobial Activity Yes (bacteria, fungi, viruses)
Key Targets Microbial membranes, FPR2 receptor

KPV

Structure Tripeptide (Lys-Pro-Val) from alpha-MSH
Primary Mechanism NF-kB pathway inhibition
Research Focus Intestinal inflammation, colitis models
Pathway Breadth Focused (NF-kB cascade)
Antimicrobial Activity No direct antimicrobial activity
Key Targets NF-kB transcription factors

The Verdict

LL-37 and KPV both appear in immune and inflammation research but operate through fundamentally different mechanisms. LL-37 functions as both a direct antimicrobial agent and an immunomodulatory signal, making it valuable in study models involving microbial challenge. KPV is a focused NF-kB pathway inhibitor without antimicrobial activity, making it more precise for studying inflammation independent of infection. Researchers studying complex wound or gut environments may use both to address structural defense and inflammatory regulation simultaneously.

LL-37 vs KPV — FAQ

Is LL-37 only an antimicrobial peptide?
No. While LL-37 was initially characterized for its broad-spectrum antimicrobial activity, subsequent research has revealed significant immunomodulatory and pro-repair functions including angiogenesis promotion and NF-kB modulation.
How does KPV inhibit inflammation?
KPV directly interferes with the NF-kB signaling pathway, which is a master regulator of pro-inflammatory gene expression. It does not engage melanocortin receptors despite being derived from alpha-MSH.
Can they be studied together?
Yes. Their mechanisms are distinct — LL-37 addresses both microbial challenge and immune modulation, while KPV focuses purely on NF-kB inflammation. Combined protocols can be useful in models with both infection and inflammation components.
What is the regulatory status?
Both are sold as research-use-only compounds for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. LL-37, the only human member of the cathelicidin family of antimicrobial peptides — PubMed / Biochim Biophys Acta . Foundational review of LL-37 antimicrobial and immunomodulatory functions.
  2. KPV, an alpha-MSH tripeptide analogue, attenuates murine colitis — PubMed / J Pharmacol Exp Ther . Key preclinical source demonstrating KPV anti-inflammatory activity via NF-kB inhibition.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides Category
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now